Arne advises on public and private transactions, leveraged buy-outs and complex cross-border transactions and corporate restructurings. 
Arne has been repeatedly recognised as a leader in his field, having been nominated for the Best M&amp;A Lawyer Award since 2007. He won the award “Best M&amp;A Lawyer” in 2013, 2014, 2015, 2016, 2017 and 2018. Legal 500 EMEA has also consistently named him a leading individual from 2009. Moreover, IFLR 1000 has recognised Arne as one of the leading practitioners in mergers and acquisitions every year since 2006. Arne was named “Lawyer of the Year” in the Best Lawyers 2014-2015 edition (Netherlands community) in Corporate Law, Mergers and Acquisitions Law and Private Equity Law.
 In 2018 he was also inducted into the Legal 500 Hall of Fame. His many accolades include being ranked first tier in M&amp;A and private equity by Chambers. 
Arne is a trusted adviser to many of his clients, and counts among his diverse client base Philips, AkzoNobel, NXP, Rabobank, BAM, Corbion, Arcadis, Bain Capital, Gilde, CVC Capital, and Schiphol Airport. 
Arne's recent work includes advising and representing:
<ul><li>AkzoNobel on the unsuccessful hostile public offer by PPG Industries and advised in its dealings with activist shareholder Elliott Advisors, and successfully defended AkzoNobel in court cases initiated by Elliott Advisors</li><li>Philips on numerous M&amp;A transactions including the EUR 862 million IPO of Philips Lighting; and the sale of Philips’ 80.1% interest in Lumileds to Apollo</li><li>NXP on numerous strategic transactions including the USD 40 billion merger with Freescale, the EUR 2.75 billion sale by NXP of its Standard Products division to JAC Capital and on the USD 47 billion public offer by Qualcomm</li><li>Bpost on the unsuccessful public offer on PostNL</li><li>Shareholders of Q-Park on their EUR 2.95 billion divestment of shares to KKR Infrastructure</li><li>Bain Capital Private Equity on the acquisition of Bugaboo</li></ul>

Arne grimmeextra2

Arne Grimme

Partner

Martin is acclaimed in the Netherlands for his expertise in corporate law, mergers and acquisitions and corporate governance. He regularly advises in public offers, stakeholder activism and other strategic issues. Martin is trusted adviser to many listed and private companies.
Martin’s recent work includes advising: 
<ul><li>FCA on its merger with Peugeot</li><li>Altice on Next Private's public offer</li><li>Qiagen on its aborted merger agreement with Thermo Fisher </li><li>Altice on the spin off of Altice USA</li><li>Signify on its IPO</li><li>Heineken Holding on the amendment of its corporate governance, including the abolishment of priority shares</li><li>AkzoNobel on its demerger of the Specialty Chemicals Business</li><li>Ahold on its merger with Delhaize</li><li>ABN AMRO on its IPO</li><li>Rabobank on the restructuring of more than 100 banks into one Rabobank</li><li>ING on the amendment of its corporate governance, including the abolishment of depositary receipts for shares</li></ul>

Martin vanolffen

Martin van Olffen

Bernard spoor

Bernard Spoor

Other...

Casper represents clients in complex business transactions and advises them on general corporate and governance matters.
Casper has significant experience in assisting companies listed in the Netherlands or elsewhere with the corporate law aspects of domestic or cross-border transactions, spin-offs and securities offerings.
Casper's recent work includes advising: 
<ul><li>Arya Sciences Acquisition Corp. on its joint venture with Immatics Biotechnologies GmbH and its listing on NASDAQ</li>
 <li>TechnipFMC on the separation and Euronext Paris listing of its Technip Energies business</li>
 <li>Qiagen on the USD 12.5 billion offer of Thermo Fisher Scientific</li>
 <li>Pfizer on the USD 22 billion merger of spin-offs Upjohn and Mylan</li>
 <li>RELX on the discontinuation of its dual-headed structure</li>
 <li>CB&amp;I on its USD 6 billion combination with McDermott</li>
 <li>Elastic on its IPO on NYSE </li>
 <li>Signify on its IPO on Euronext Amsterdam</li>
 <li>Avast on its acquisition of NYSE-listed AVG Technologies</li>
 <li>Prosensa on its IPO on Nasdaq and the subsequent USD 840 million offer by Biomarin</li>
 <li>NXP on its acquisition of NASDAQ-listed Freescale Semiconductors</li>
 <li>ABN AMRO Group on its IPO on Euronext Amsterdam and the subsequent simplification of its group structure</li>
 <li>Rabobank on the listing of its depositary receipts on Euronext Amsterdam</li>
</ul>

Casper nagtegaal

Casper Nagtegaal

Frank specialises in complex public and private M&amp;A transactions. He has acted for several listed companies, large multinationals and private equity funds on M&amp;A transactions, joint ventures, corporate governance and listing rules. A substantial part of his practice involves cross-border transactions, advising clients on their transactions outside of the Netherlands. Aside from transaction focused matters, Frank regularly advises listed companies on shareholder activism and response situations, including hostile takeover bids. Prior to joining the M&amp;A team, he worked as a senior associate in the firm's Corporate Litigation practice.

Frank hamming

Frank Hamming

Eveline specialises in corporate law with a focus on the corporate advisory practice. Since joining De Brauw in January 2016, Eveline has advised a wide range of listed, private, founder-led and state-owned companies on corporate governance related matters, their corporate structuring and anti-takeover measures. She has also been involved in various national and international transactions, including IPOs, joint-ventures and public and private M&amp;A.

Eveline dewaard

Eveline de Waard

Senior Associate

Ioana patrascu

Ioana Patrascu

Matthijs advises listed companies, large multinationals and private equity clients on national and cross-border M&amp;A transactions and joint ventures. Matthijs also regularly advises businesses and corporations on their corporate structure and governance.

Matthijs verwer

Matthijs Verwer

Pim focuses on advising on the tax aspects of mergers and acquisitions, spin‑offs, reorganisations, securities offerings, bank financings and litigations, both domestically and internationally.

Pim siemons

Pim Siemons

Associate

<a href="https://www.thermofisher.com/nl/en/home.html">Thermo Fisher Scientific</a>, the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their businesses and create a leading global biotechnology company. 
This was the first German/US public offer ever made for a Dutch NV company. As lead counsel to <a href="https://www.qiagen.com/us/">QIAGEN</a>, we led an international team of lawyers advising QIAGEN on this multi-billion cross-border transaction. 
Read more about this deal <a href="https://corporate.qiagen.com/newsroom/press-releases/2020/20200303_thermo_acquires_qiagen?cmpid=CCOM_NON_NON_TQ_0320_SM_TwitterOrg_PR">here.</a> 
De Brauw team: <a href="https://www.debrauw.com/people/arne-grimme/">Arne Grimme</a>, <a href="https://www.debrauw.com/people/martin-van-olffen/">Martin van Olffen</a>, <a href="https://www.debrauw.com/people/bernard-spoor/">Bernard Spoor</a>, <a href="https://www.debrauw.com/people/casper-nagtegaal/">Casper Nagtegaal</a>, <a href="https://www.debrauw.com/people/frank-hamming/">Frank Hamming</a>, <a href="https://www.debrauw.com/people/eveline-de-waard-2/">Eveline de Waard</a>, <a href="https://www.debrauw.com/people/ioana-patrascu/">Ioana Patrascu</a>, <a href="https://www.debrauw.com/people/matthijs-verwer/">Matthijs Verwer</a>, <a href="https://www.debrauw.com/people/maarten-van-der-weijden/">Maarten van der Weijden</a>, <a href="https://www.debrauw.com/people/klaas-versteeg/">Klaas Versteeg</a> and <a href="https://www.debrauw.com/people/pim-siemons/">Pim Siemons</a>.

Mergers & 
Acquisitions

Corporate Advisory 
& Corporate Governance

Home

Matter overview

Thermo Fisher Scientific to acquire QIAGEN

Breadcrumbs

De Brauw is widely recognised as a leading international law firm in the Netherlands. For nearly 150 years, we have been standing by our clients as a strong and spirited collective of leading legal experts. Through profound engagement with the business of our clients and a deep understanding of their ambitions, we build relationships of trust - some of which already stand for more than one hundred years.

De Brauw Blackstone Westbroek

Thermo Fisher Scientific , the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their businesses and create a leading global biotechnology company.  This was the first German/US public offer ever made for a Dutch NV company. As lead counsel to QIAGEN , we led an international team of lawyers advising QIAGEN on this multi-billion cross-border transaction. Read more about this deal here.  De Brauw team: Arne Grimme , Martin van Olffen , Bernard Spoor , Casper Nagtegaal , Frank Hamming , Eveline de Waard , Ioana Patrascu , Matthijs Verwer , Maarten van der Weijden , Klaas Versteeg and Pim Siemons .

Thermo Fisher Scientific , the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their…

description

generator

law firm,lawyer,legal,legal firm,amsterdam,international law firm

keywords

https://dwbxnuhxoazve.cloudfront.net/Icons/_1200x630_crop_center-center_82_none/og_image.png?mtime=1710424428

https://www.linkedin.com/company/de-brauw-blackstone-westbroek/

https://www.facebook.com/careersatdebrauw

https://www.debrauw.com/matters/thermo-fisher-scientific-to-acquire-qiagen

referrer

robots

twitter:card

twitter:creator

twitter:description

https://dwbxnuhxoazve.cloudfront.net/Icons/_800x418_crop_center-center_82_none/og_image.png?mtime=1710424428

Areas of expertise

Sector

Topic